ePrints

I am SAMD9L: 7q regulator I am

Lookup NU author(s): Professor Matthew CollinORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2017 by The American Society of Hematology. The SAMD9L gene and its paralog SAMD9, sitting head to tail on chromosome 7q, are among the notable absences in -7/7q- myelodysplastic syndromes (MDSs). As with many other genes harboring somatic mutation in neoplasia, germ line variants often provide critical insights into the mechanisms of dysfunction. In this issue of Blood, Tesi et al provide tantalizing new details to the story of SAMD9L mutation and familial -7/7q- syndromes.1 This widely expressed protein normally functions to inhibit proliferation and is therefore a potential tumor suppressor gene. The authors find 2 novel gain-of-function (GoF) variants that are associated with cytopenias, immunodeficiency, and neurological dysfunction and show how these can be ameliorated by coinherited loss-of-function alleles, or by somatic reversion of the mutated alleles in the bone marrow. When the progenitor ecosystem fails to select benign revertant clones, a predisposition to -7/7q- MDS is observed, otherwise known as the familial condition of ataxia-pancytopenia syndrome (ATXPC; Mendelian Inheritance in Man no. 159550). Neurological consequences, although variable, are not remedial by reversion mutation.

Publication metadata

Author(s): Collin M

Publication type: Note

Publication status: Published

Journal: Blood

Year: 2017

Volume: 129

Issue: 16

Pages: 2210-2212

Online publication date: 20/04/2017

Acceptance date: 02/04/2016

ISSN (print): 0006-4971

ISSN (electronic): 1528-0020

Publisher: American Society of Hematology

URL: https://doi.org/10.1182/blood-2017-03-770198

DOI: 10.1182/blood-2017-03-770198

Share